APA (7th ed.) Citation

M, O., M, W., A, M., G, B., A, S., & E, K. (2026). Targeting BCL-2 and PI3K signaling pathways enhances cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cells. Biochemical and biophysical research communications, 817, 153752. https://doi.org/10.1016/j.bbrc.2026.153752

Chicago Style (17th ed.) Citation

M, Opydo, Wojtaszek M, Mosurek A, Burczyk G, Such A, and Kolaczkowska E. "Targeting BCL-2 and PI3K Signaling Pathways Enhances Cytotoxicity of Gemtuzumab Ozogamicin Against Acute Myeloid Leukemia Cells." Biochemical and Biophysical Research Communications 817 (2026): 153752. https://doi.org/10.1016/j.bbrc.2026.153752.

MLA (9th ed.) Citation

M, Opydo, et al. "Targeting BCL-2 and PI3K Signaling Pathways Enhances Cytotoxicity of Gemtuzumab Ozogamicin Against Acute Myeloid Leukemia Cells." Biochemical and Biophysical Research Communications, vol. 817, 2026, p. 153752, https://doi.org/10.1016/j.bbrc.2026.153752.